If you live with Crohn's disease, you know the hard part is not just the flares. It is the cycle: a medicine works for a while, then slowly stops working, and you move on to the next one. For years the list of "next ones" was short. In 2025 it grew twice in just three months, and a completely new type of medicine, one that targets something no approved drug touches, is now in its final round of testing.
About 1 in 100 Americans live with inflammatory bowel disease, and Crohn's makes up close to half of those cases. This article covers what treatment looks like today, why surgery is still so common, what researchers are testing right now, and where clinical trials fit in. If you were diagnosed with the related condition instead, our ulcerative colitis guide covers that side.
Looking for treatment options for Crohn's Disease?
Browse open Crohn's Disease clinical trials near you! We'll handle the follow-up.
What Crohn's disease treatment includes today
Treatment has one main goal now, and it changed how trials are run: not just feeling better, but a healed bowel lining that a doctor can actually see on a colonoscopy. Doctors call this mucosal healing, and it predicts fewer flares, fewer hospital stays, and less surgery down the road.
The older tools. Steroids calm a flare quickly but are not meant to be used long term. Immunomodulators like azathioprine and methotrexate work more slowly to hold back the immune system, and are often paired with a biologic.
Biologics, the backbone since 1998. Infliximab (Remicade) was the first one. TNF blockers, including adalimumab (Humira), are still the most used type. Vedolizumab (Entyvio) works only in the gut, by keeping immune cells from getting in there in the first place. Ustekinumab (Stelara) blocks two inflammation signals at once, and now comes in several cheaper generic style versions.
The 2025 wave of new drugs. Risankizumab (Skyrizi) was approved for Crohn's in 2022. Then in January 2025 the FDA approved mirikizumab (Omvoh), and in March 2025 guselkumab (Tremfya) followed, the first drug in this class that can be started either by IV or by an injection you give yourself at home. Getting three new drugs in one class in three years is fast for this disease.
The oral option. Upadacitinib (Rinvoq) was approved for Crohn's in 2023 for people who did not respond to a TNF blocker. It is the first pill of its kind for Crohn's, and it comes with safety warnings that affect who can take it.
Surgery. About 26 percent of people with Crohn's have surgery within 10 years of diagnosis, and the rate is consistently higher than in ulcerative colitis. Surgery can bring years of relief, but it does not cure Crohn's, the disease can come back in whatever bowel is left. That single fact is a big reason the drug pipeline matters more here than in almost any other gut disease.
What researchers are studying now
TL1A blockers, the type everyone is watching. TL1A is a protein that drives both inflammation and scarring in the gut, and no approved medicine targets it yet. Roche's afimkibart is now in its final round of testing for Crohn's, with an induction and maintenance study and a separate induction study both recruiting on our platform. Researchers are excited about this type because it may slow down the scarring that leads to narrowed bowel, something no current drug can do.
A new kind of pill. Takeda's zasocitinib (TAK-279) blocks a signal called TYK2, which is related to the JAK pathway but more targeted, so it may come with fewer of the safety concerns JAK inhibitors carry. It is being tested in people with moderate to severe Crohn's.
Cell therapy for fistulas. Perianal fistulas, tunnels that form between the bowel and skin, are one of the hardest problems in Crohn's to treat. Two studies on our platform are testing approaches using stem cells: a trial injecting stem cell derived material directly into the fistula, and a broader study of stem cells taken from fat tissue for Crohn's.
Seeing the difference between scar and inflammation. When part of the bowel narrows, treatment depends on whether it is active inflammation, which medicine can help, or scar tissue, which usually needs surgery. A study testing a new PET scan tracer is looking at whether imaging can tell the two apart without needing surgery to find out.
Getting more out of the drugs we already have. One study is asking whether people in stable remission on ustekinumab can safely space out their doses. Another is comparing a home injection version of vedolizumab against the IV version. And a study on gut bacteria is testing whether they can predict who will respond to which medicine, which could save people months on a drug that was never going to work for them.
Why Crohn's research takes time
The colonoscopy problem. Feeling better is not enough on its own. Regulators want to actually see a healed bowel lining, so trials check participants with a scope at set points along the way, and an independent expert reviews the images. That makes the results trustworthy, but it also makes trials longer and a real commitment for the people in them.
The two stage problem. Crohn's trials usually run in two parts: first, does the drug work within 12 weeks, then, does it still work a year later. A drug has to pass both stages. That is the right bar to set for a disease people live with for life, but it is also why these programs take years to finish.
The moving target problem. Crohn's changes over time. Inflammation can turn into scarring and narrowing over the years, and a medicine that calms inflammation well may do nothing for scar tissue. Because of this, newer trials increasingly focus on one type of disease behavior at a time, which gives cleaner results but makes it slower to find enough people to enroll.
The representation problem. IBD was long thought of as a disease mostly affecting white Americans, and trials recruited that way. White adults still have the highest prevalence, but CDC analysis of older Medicare patients found that between 2001 and 2018 diagnosed IBD rose faster among Black patients than white ones. Black patients remain underrepresented in studies. Here's why diversity in clinical trials matters so much.
Common myths about Crohn's disease
"Crohn's is caused by stress or bad diet."
No. It comes from genes, the immune system, gut bacteria, and environment. Stress and certain foods can make symptoms worse, but they do not cause the disease, and no diet cures it.
"Surgery cures Crohn's."
It does not. Removing a damaged section brings relief, sometimes for years, but Crohn's can return in the remaining bowel. That is different from ulcerative colitis, where removing the colon removes the disease.
"Crohn's and ulcerative colitis are basically the same."
They are cousins, not twins. Crohn's can appear anywhere from mouth to anus and goes through the whole bowel wall. UC stays in the colon's inner lining. They are treated differently and studied separately.
"Biologics are a last resort."
Outdated. Growing evidence supports starting effective treatment early, before damage builds. Many trials now enroll people who have never taken a biologic.
How Crohn's is classified, and what care usually looks like
Doctors describe Crohn's by where it is (small bowel, colon, or both) and how it behaves (causing inflammation, narrowing the bowel, or forming tunnels called fistulas), plus how active it is: mild, moderate, or severe. Typical care looks like this: mild disease may only need budesonide or a short course of steroids. Moderate to severe disease usually means a biologic or a JAK inhibitor, often along with an immunomodulator. Narrowing and fistulas bring surgeons into the picture too, alongside medicine. This describes usual practice, not a recommendation, your plan belongs to you and your gastroenterologist.
For trials, "moderately to severely active" is the phrase you will see in most study titles, and specific types like perianal fistulas get their own separate studies. Your last colonoscopy report has the details you need to filter studies in minutes.
How to find a Crohn's disease clinical trial
AllClinicalTrials.com lists Crohn's studies recruiting across the US, everything from late stage drug trials to fistula cell therapy and studies on how to manage treatment long term. Two examples recruiting right now: Roche's late stage study of afimkibart, the TL1A blocker, for moderately to severely active Crohn's, and a study comparing a home injection version of vedolizumab against the IV version.
The application takes about 5 minutes: you answer questions about your diagnosis, current medicines, and disease history, and if a study near you looks like a match, the research team reaches out to you. Nothing is decided until you have gone through informed consent, and taking part is voluntary the whole way through. Three things to have ready: your current Crohn's medicines, the location and behavior of your disease from your last colonoscopy, and whether you have had bowel surgery.
Common questions
What is the newest treatment for Crohn's disease? The newest approved medicines are the IL-23 blockers mirikizumab (Omvoh, January 2025) and guselkumab (Tremfya, March 2025). The most watched pipeline class is TL1A blockers, now in Phase 3, which may address scarring as well as inflammation.
What is the best treatment for Crohn's disease? There is no single best. TNF blockers, IL-23 blockers, vedolizumab, ustekinumab, and the JAK inhibitor upadacitinib all work for different people, and the right choice depends on disease location, behavior, severity, and what you have tried. Starting effective treatment early is increasingly the shared principle.
Can Crohn's disease go into remission? Yes. Remission means few or no symptoms and, ideally, a healed bowel lining on colonoscopy. Many people reach it on modern medicines, and studies are now testing whether people in long remission can safely reduce their doses.
Do Crohn's disease trials use placebo? Often in the induction phase, yes, but participants usually stay on some background treatment, and most trials move everyone to the active drug afterward or in an extension study. Withholding all treatment from active Crohn's would be unethical, and trial designs reflect that.
See Crohn's disease clinical trials recruiting now
Browse open studies, filter by location, and apply in about 5 minutes: Crohn's Disease Clinical Trials